SELLAS Life Sciences Group, Inc.
Financials
Valuation Metrics
SELLAS Life Sciences Group, Inc.'s Market Cap is $2.32B. At end of 2025 it was $577M. Ranked #1923 of 3,121 in US market (top 62%), #722 of 1,463 on NASDAQ (top 49%), #123 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.32B | US#1,923/3,121 Sec#123/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-32M | US—/3,121 Sec—/266 |
| Total Assets | $145M | US#3,035/3,121 Sec#256/266 |
| Net Assets | $138M | US#2,766/3,121 Sec#210/266 |
| Employees | 13 | US#2,781/3,121 Sec#223/266 |
| Value | ||
| P/B | 16.86x | US#2,760/3,121 Sec#214/266 |
| FCF Yield | -1.22% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -23.58% | US#2,520/3,121 Sec#101/266 |
| ROA | -22.33% | US#2,823/3,121 Sec#134/266 |
| Financial Health | ||
| Debt Ratio | 5.61% | US#45/3,121 Sec#18/266 |
| Total Debt | $737000.00 | US#2,991/3,121 Sec#247/266 |
| FCF | $-28M | US#2,465/3,121 Sec#101/266 |
| Cash | $138M | US#2,001/3,121 Sec#141/266 |
| Current Ratio | 18.83x | US#125/3,121 Sec#29/266 |
| Performance | ||
| 1Y Return | 613.66% | US#6/3,121 Sec#4/266 |
| 1M Return | -17.04% | US#2,622/3,121 Sec#198/266 |
| From 52W High | -27.64% | US#1,921/3,121 Sec#149/266 |
| 1Y MDD | -36.24% | US#1,816/3,121 Sec#124/266 |
| Trading | ||
| Volume | 12,592,812 shares | US#358/3,121 Sec#28/266 |
| Trading Value | $144M | US#1,204/3,121 Sec#91/266 |
| Per Share | ||
| EPS | $-0.16 | US—/3,121 Sec—/266 |
| BPS | $0.68 | US#2,739/3,121 Sec#214/266 |
Company Info
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.